Income statement, balance sheet and cash flow statement for the last 2 fiscal years, taken from the XBRL data LB PHARMACEUTICALS INC files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2025
FY2025
Research and development
51.2
16.7
General and administrative
13.7
13.7
Operating expenses
64.8
30.4
Interest income
1.72
3.92
Other non-operating income
1.73
5.2
Pre-tax income
-63.1
-25.2
Income tax
0
0
Net income
-63.1
-25.2
EPS, basic
-176.15
-3.13
EPS, diluted
-176.15
-3.13
Shares, basic (weighted)
0.36
8.05
Shares, diluted (weighted)
0.36
8.05
Balance sheet
FY2025
FY2025
Cash and equivalents
23
250
Short-term investments
5.02
45
Other current assets
0.88
13.2
Total current assets
28.9
308
Property, plant and equipment
1.86
1.58
Lease right-of-use assets
2.3
2.15
Total assets
33.5
313
Accounts payable
2.32
2.13
Accrued liabilities
5.3
4.59
Total current liabilities
8.11
7.44
Lease liabilities
3.22
2.84
Total liabilities
13.8
11.6
Paid-in capital
9.66
431
Retained earnings
-104
-130
Other comprehensive income
0.11
0.17
Shareholders' equity
-94.6
301
Total equity
-94.6
301
Total liabilities and equity
33.5
313
Shares outstanding
0.25
25.3
Cash flow statement
FY2025
FY2025
Net income
-63.1
-25.2
Depreciation and amortization
0.09
0.32
Stock-based compensation
3.09
4.19
Deferred income tax
0
0
Change in payables
5.02
-0.91
Cash from operations
-53.1
-35.2
Capital expenditures
-0.77
-0.05
Purchases of investments
-29.7
-44.8
Sales and maturities of investments
30.1
2.5
Cash from investing
23.2
-39.9
Cash from financing
38.3
303
Net change in cash
8.5
227
Free cash flow
-53.8
-35.3
Income taxes paid
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $37.33 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-25.8%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-23.7%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Total assets growth, 1y
833.2%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
2,146.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
15.1x
Current assets / current liabilities.
Quick ratio
13.9x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
13.9x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-$2.75
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$2.73
Cash from operations / diluted weighted shares.
Book value per share
$11.59
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
3.62x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
3.62x
Market cap / tangible book value, when positive.
FCF yield
-6.9%
Free cash flow / market cap.
Earnings yield
-7.1%
Net income / market cap (the inverse of P/E).
Was LB PHARMACEUTICALS INC profitable in fiscal 2025?
No. It reported a net loss of $25.2M.
How much free cash flow did LB PHARMACEUTICALS INC generate in fiscal 2025?
Cash from operations of $35.2M minus capital expenditures of $52.0K left free cash flow of -$35.3M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.